TRAJENTA® meta analysis: No increased cardiovascular (CV) risk.

In the placebo-controlled cohort of a pooled analysis of 19 double-blind, randomised controlled studies that included over 7,000 patients with T2D, linagliptin demonstrated no increased cardiovascular risk; 4P-MACE incidence per 1,000 patient-years rates were:†1
  • 14.9 for linagliptin1
  • 16.4 for placebo1

The ongoing CARMELINA® trial:2

  • Is a unique trial as it is evaluating cardiovascular safety and renal outcomes with treatment with linagliptin
  • Aimed to recruit a unique population of patients with macrovascular and renal burden
  • CARMELINA® will provide evidence to the long term clinical-safety profile of linagliptin.

Click here for more information

CAROLINA®, the only DPP4i cardiovascular outcome trial with an active comparator (glimepiride), is investigating cardiovascular outcomes in type 2 diabetes.3-5

Click here for more information

A prospective meta-analysis of independently adjudicated cardiovascular events from nineteen clinical studies (ranging from 18 weeks to 24 months duration). Primary endpoint: Composite of prospectively adjudicated CV death, non-fatal myocardial infarction, non-fatal stroke and hospitalisation for unstable angina (4P-MACE).